Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| R&D Facilities |
 |
 |
 |
| Our understanding and expert knowledge in the field of particle design, solid-state control and supercritical fluid technologies, enables us to take the right steps right away to achieve your goals. View Larger Map We work together with our clients to rapidly obtain the results they need by using a pragmatic go/no go approach. R & D facilities Pol. Ind. La Bòbila Carrer de Portugal, 33/35 View Larger Map08290 Cerdanyola del Vallès Phone/Fax : +34 935947011 View Larger Map A reduction in particle size generates a corresponding increase in surface area. A size reduction form a ‘standard’ 5 µm particle to 0.2 µm nanoparticles will increase the nominal surface area by a factor of 25. A larger surface area creates a greater possibility for dissolution in a solvent, which can lead to significantly increased dissolution rates.head View Larger Map View Larger Map http://maps.google.com/maps/place?cid=26759652904668683&q=activery&hl=en&cd=1&ei=qkrsTJ3FJobSjAeErYDDBg&dtab=0&sll=41.502921,2.225418&sspn=0.204154,0.614548&ie=UTF8&ll=41.638026,1.917801&spn=0,0&z=11 http://maps.google.es/maps/place?cid=26759652904668683&q=activery&hl=es&ved=0CCIQ-QswAA&ei=zkjsTLq2MqLMjAeQ5qWWDQ&sll=41.477005,2.117234&sspn=0.068316,0.085492&ie=UTF8&ll=41.678041,1.50238&spn=0,0&z=10 http://maps.google.es/maps/place?cid=26759652904668683&q=activery&hl=es&ved=0CCIQ-QswAA&ei=zkjsTLq2MqLMjAeQ5qWWDQ&sll=41.477005,2.117234&sspn=0.068316,0.085492&ie=UTF8&ll=41.678041,1.50238&spn=0,0&z=10 View Larger Map |
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis